PCAC voted 7–4–1 in favor of Epitalon and 6–7–1 against emideltide (DSIP). Semax remains pending.
PCAC advises FDA on which bulk substances should be considered for the Section 503A Bulks List. These votes are recommendations, not FDA approval or immediate changes in availability.
Watch the official July 24 PCAC live stream on YouTube.
Rebody's PCAC peptide vote tracker lists every verified tally beside the official webcast.
Epitalon: 7 yes, 4 no, 1 abstention
FDA reviewed Epitalon free base and Epitalon acetate for insomnia. The favorable vote puts the committee's support on the record for FDA to consider.
Read the updated Epitalon PCAC result.
Emideltide: 6 yes, 7 no, 1 abstention
FDA reviewed emideltide free base and emideltide acetate for chronic insomnia, narcolepsy, and opioid withdrawal. The unfavorable vote leaves those nominations without committee backing.
Read the updated emideltide PCAC result.
Semax vote still to come
Semax is the final peptide on the July 24 agenda. FDA reviewed Semax for cerebral ischemia, migraine, and trigeminal neuralgia. We will add the tally after it appears on the official webcast.
PCAC peptide results
- BPC-157: favorable, 8–6–1
- KPV: favorable, 8–6–1
- TB-500: favorable, 8–6–1
- MOTS-c: favorable, 7–5–2
- Emideltide (DSIP): unfavorable, 6–7–1
- Epitalon: favorable, 7–4–1
- Semax: pending
PCAC Day 2 FAQ
What did FDA review Epitalon for?
FDA reviewed Epitalon free base and Epitalon acetate for insomnia.
What did FDA review emideltide for?
FDA reviewed emideltide free base and emideltide acetate for chronic insomnia, narcolepsy, and opioid withdrawal.
Are the PCAC votes final FDA decisions?
No. PCAC advises FDA; its votes do not change the Section 503A Bulks List.